“Unleashing the Power of Zenocutuzumab: The Revolutionary Treatment for NRG1 Fusion-Positive Cancer, as Featured in the New England Journal of Medicine”
Exciting Developments in Cancer Treatment Breaking News: Merus N.V. Announces NEJM Publication UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, has just revealed the groundbreaking results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab). This innovative treatment is the first of its…